Curis Lifesciences Ltd
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Curis Lifesciences Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
IPO Snapshot
Key metrics and details at a glance.
Price Band
₹128
Per ShareLot Size
1000 Shares
Minimum Investment
₹1,28,000
Issue Size
₹27.52 Cr
Face Value
₹10
Per ShareIPO Type
Book Building - SME
Retail Quota
35.06%
QIB Quota
49.85%
NII Quota
15.09%
IPO Timeline
Important dates for your applying strategy.
Subscription Status
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Curis Lifesciences Ltd
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
92.68%
Promoter Holding (Post-Issue)
68.03%
Issue Type
Book Building - SME
ISIN
INE1BZN01016
About the Company
Curis Lifesciences is the pharma manufacturer, specializing in manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, Oral Liquid, Sterile Ophthalmic Ointments. We operate in global as well as domestic markets. We undertake manufacturing activities on loan license, Contract Manufacturing and Direct Export basis/Own Brand Marketing basis. In terms of the nature of manufacturing and business activities,
Industry Overview
Indian pharmaceutical industry is known for its generic medicines and low-cost vaccines globally. Transformed over the years as a vibrant sector, presently the Indian Pharmaceutical industry is the third largest in the world in terms of volume and 14th largest in terms of value. The pharma sector currently contributes to around 1.72% of the country's GDP. The Indian pharmaceuticals industry is expected to grow 9-11% in the financial year 2024, as per ICRA. In FY23, the Indian pharma market saw a year-on-year growth of nearly 5%, reaching US$ 49.78 billion. During FY18 to FY23, the Indian pharmaceutical industry logged a compound annual growth rate (CAGR) of 6-8%, primarily driven by an 8% increase in exports and a 6% rise in the domestic market. Major Segments of the Pharmaceutical Industry are Generic drugs, OTC Medicines and API/Bulk Drugs, Vaccines, Contract Research & Manufacturing, Biosimilars & Biologics. Market size of India pharmaceuticals industry is expected to reach US$ 65 billion by 2024, ~US$ 130 billion by 2030 and ~US$ 450 billion market by 2047.
Company History
Our Company was originally formed and registered as a Partnership Firm under the Partnership Act, 1932 ("Partnership Act") in the name and style of "Loreto Pharmaceuticals", pursuant to a deed of partnership dated June 2, 2010. Thereafter "Loreto Pharmaceuticals" was converted from Partnership Firm to a Private Limited Company under the Companies Act, 2013 in the name of "Curis Lifesciences Private Limited" and received a certificate of incorporation dated March 23, 2016 issued by Assistant Registrar of Companies, Gujarat. Subsequently, our Company was converted into a public limited company and the name of our Company was changed from "Curis Lifesciences Private Limited" to "Curis Lifesciences Limited" vide Special Resolution dated May 6, 2024, the status of the Company was changed to public limited and the fresh certificate of incorporation consequent to conversion, bearing Corporate Identification Number U24230GJ2016PLC086559, was issued on August 9, 2024 by the Assistant Registrar of Companies/ Deputy Registrar of Companies/ Registrar of Companies, Central Processing Centre. Registered Office: PF-23, GIDC Sanand - II, Industrial Estate, Ahmedabad, Sanand, Gujarat -382110, India.
Products & Services
- Curis Lifesciences is the pharma manufacturer, specializing in manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, Oral Liquid, Sterile Ophthalmic Ointments.
Growth Strategy
- Improve global presence.
- Leveraging our market skills and relationship.
- Maintaining edge over competitors.
- Customer Satisfaction.
Customer Base
Wholesaler and Retailer
Financial Performance
Revenue, profit after tax and total assets across the last 3 reported financial years.
Revenue
Amount in ₹ crore
Profit After Tax (PAT)
Amount in ₹ crore
Total Assets
Amount in ₹ crore
Figures in ₹ crore, on a standalone basis, as reported for FY23 to FY25.
Objects of the Issue
How the company plans to utilize IPO proceeds.
Use of Proceeds
The funds raised through this IPO will be used for:
initial public issue of 21,50,000 equity shares of face value of Rs. 10/- each of Curis Lifesciences Limited ("Curis" or the "company" or the "Issuer") for cash at a price of Rs. 128/- per equity share including a share premium of Rs. 118/- per equity share (the "Issue Price") aggregating to Rs. 27.52 crores ("the Issue"), of which 1,08,000 equity shares of face value of Rs. 10/- each for cash at a price of Rs. 128/- per equity share including a share premium of Rs. 118/- per equity share aggregating to Rs. 1.38 crores will be reserved for subscription by market maker to the issue (the "Market Maker Reservation Portion"). The issue less the market maker reservation portion i.e. net issue of 20,42,000 equity shares of face value of Rs. 10/- each at a price of Rs. 128/- per equity share including a share premium of Rs.118/- per equity share aggregating to Rs. 26.14 crores is herein after referred to as the "Net Issue". The issue and the net issue will constitute 26.59% and 25.26%, respectively, of the post issue paid up equity share capital of the company.
*Subject to approvals and market conditions.
Strengths & Risks
Key competitive advantages and factors to consider before investing.
- Experienced Promoters and Management Team.
- Wide range of Products.
- Strategic Location of Manufacturing Facility.
- Scalable Business Model.
- Quality assurance.
- Our manufacturing facility is concentrated in Sanand, Ahmedabad, Gujarat, exposing us to risks from economic, regulatory, political, and other regional changes, including natural disasters, which could negatively impact our business operations, financial performance, and overall condition.
- As a pharmaceutical company, we operate in a highly regulated industry where our business relies on obtaining approvals from relevant regulatory and health authorities. Delays or failures in securing or renewing these essential approvals, registrations, or changes in the regulatory environment for marketing our products in regulated markets could have a significant impact on our business and strategy, ultimately affecting our overall profitability.
- Our business operations are subject to fluctuations in raw material prices.
- The company relies on a limited number of customers for its sales, and the loss of any major customer could adversely impact our revenue and profitability.
- The company relies on a limited number of suppliers for product procurement, and the loss of any key supplier could impact our business operations.